Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer

Esophageal Cancer Clinical Trial

Official title:

A Pilot Study of the Biologic Efficacy and Safety of the Addition of Celecoxib to a Program of Induction Chemotherapy and Neo-Adjuvant Chemo-Radiotherapy for the Treatment of Esophageal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00520091
• Other study ID #: LCCC 0203
• Secondary ID: CDR0000561610
• Status: Completed
• Phase: Phase 2
• First received: August 21, 2007
• Last updated: May 16, 2012
• Start date: March 2005
• Est. completion date: September 2010

Study information

• Verified date: May 2012
• Source: UNC Lineberger Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy and radiation therapy together with celecoxib may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving irinotecan and cisplatin together with radiation therapy with or without celecoxib works in treating patients with stage II, stage III, or stage IV esophageal cancer.

Description:

OBJECTIVES:

Primary

• To measure the rates of cellular apoptosis and proliferation at baseline and during chemoradiotherapy with and without celecoxib using biopsy samples from patients with stage II, III, or IV esophageal cancer.

• To determine if an acceptable rate of pathologic complete remission can be achieved in a subset of patients with potentially resectable esophageal cancer.

Secondary

• To assess the safety of the addition of daily celecoxib to chemoradiotherapy.

• To estimate the median overall survival in a subset of patients with resectable disease.

• To quantitate expression of cyclooxygenase (COX)-2 and formation of prostaglandin E2 (PGE2) in patients with esophageal cancer.

• To assess the ability of celecoxib to decrease formation of PGE2 in tumor tissue by measuring pre- and post-treatment tumor concentrations of PGE2.

• To quantitate downstream effects of inhibition of COX-2 function in the setting of treatment with chemotherapy.

• To measure the radiographic response rate in patients with unresectable esophageal cancer.

OUTLINE: This is a multicenter study. Patients are sequentially enrolled into 1 of 2 treatment groups.

• Group 1: Patients receive cisplatin IV over 1 hour and irinotecan hydrochloride IV over 90 minutes on days 1, 8, 22, 29, 43, 50, 64, and 71. Patients also undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 43.

• Group 2: Patients receive chemoradiotherapy as in group 1. Patients also receive oral celecoxib twice daily beginning 3 days before the initiation of chemotherapy and continuing until the completion of chemoradiotherapy.

In both groups, patients with potentially resectable disease undergo surgery no more than 12 weeks after completion of chemoradiotherapy.

Endoscopic tumor biopsy specimens are collected at baseline and on day 3 of radiotherapy. Samples are analyzed for cyclooxygenase (COX)-2 gene and protein expression; PGE2 secretion; apoptotic activity; caspase-3 activation; cytochrome c translocation; VEGF mRNA quantitation; and cellular proliferation. Laboratory techniques used include RT-PCR, IHC, enzyme immunoassay, TUNEL assay, colorimetric assay, and northern blotting.

After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 34 patients (8-10 in group 1 and 24 in group 2) will be accrued for this study.

Other known NCT identifiers

• NCT00280124

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: September 2010
• Est. primary completion date: November 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Biopsy proven squamous cell carcinoma or adenocarcinoma of the esophagus

• Lesions including the gastroesophageal junction allowed provided the tumor involves less than 2 cm of gastric cardia

• Meets 1 of the following criteria:

• Clinical stage II, III, or IV disease AND planning to receive chemoradiotherapy either for preoperative or palliative indications (group 1)

• Suitable candidate for bimodality (palliative intent) or trimodality (curative intent) therapy

• Clinical stage II or III disease AND candidate to receive chemoradiotherapy for preoperative indication followed by planned esophagectomy or esophagogastrectomy (group 2)

• Suitable candidate for trimodality (curative intent) therapy

• No tracheoesophageal fistula on bronchoscopy

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Life expectancy > 3 months (group 1)

• Not pregnant

• Adequate nutrition

• WBC = 4,000/µL

• ANC = 1,500/µL

• Platelet count = 100,000/µL

• Serum creatinine = 1.5 mg/dL

• Bilirubin = 1.5 mg/dL

• No other prior or concurrent malignancy other than curatively treated carcinoma in situ of the cervix; localized prostate cancer that was previously treated with local therapy more than 2 years ago with a PSA of less than 4 ng/mL; basal cell carcinoma of the skin; or superficial transitional cell carcinoma of the bladder

• Patients who have had a prior malignancy are eligible if they have been free of disease for = 5 years

• No serious medical or psychiatric illnesses that would preclude giving informed consent or otherwise limit survival to less than 2 years

• No history of known NSAID-induced gastrointestinal bleeding

• No current peptic ulcer disease

• No active coronary artery disease

• No myocardial infarction or cerebrovascular accident within the past 3 months

• No history of refractory congestive heart failure or cardiomyopathy

PRIOR CONCURRENT THERAPY:

• More than 1 week since prior major surgery (group 1)

• More than 2 weeks since prior major surgery (group 2)

• No prior chemotherapy or radiotherapy

• More than 30 days since prior cyclooxygenase-2 inhibitors (selective or non-selective), including, but not limited to, any of the following:

• Acetylsalicylic acid (aspirin)

• Piroxicam

• Diclofenac

• Meloxicam

• Indomethacin

• Fenoprofen

• Sulindac

• Flurbiprofen

• Tolmetin

• Ibuprofen

• Celecoxib

• Ketoprofen

• Rofecoxib

• Ketoprofen ER

• Valdecoxib

• Naproxen

• Meclofenamate

• Oxaprozin

• Mefenamic acid

• Etodolac

• Nabumetone

• Ketorolac

• No concurrent seizure medications

• No concurrent amifostine or other such agents

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms

Intervention

Drug:
• CPT- 11
65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
• Cisplatin
Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
• Celecoxib
400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin

Radiation:
• Radiation
4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks

Procedure:
• Surgery
Surgery will occur prior to chemoradiation therapy for those patients with resectable disease

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
UNC Lineberger Comprehensive Cancer Center	National Cancer Institute (NCI)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rates of cellular apoptosis and proliferation	Measure the rates of cellular apoptotis and proliferation in esophageal cancers from biopsy samples pre-study and during chemoradiation with and without celecoxib therapy	5 weeks	Yes
Primary	Rate of pathologic complete remission in patients with resectable disease	To determine if an acceptable rate of pathologic complete remissions can be achieved in a cohort of patients with potentially resectable esophageal carcinoma	4 years	No
Secondary	Number of subjects experiencing adverse events	Adverse events/toxicity will graded per the CTCAE criteria	30 days post radiation	Yes
Secondary	Median overall survival of patients with resectable disease	Follow up for survival will occur at 3 month intervals during the first two years, then every 6 months during years 3 and 4.	4 years	No
Secondary	Formation of prostaglandin E2 (PGE2) in tumor tissue	The ability of celecoxib to decrease formation of prostaglandin E2 (PGE2) in tumor tissue will be analyzed using a Wilcoxon signed rank test on the difference (log scale) of the pre- and post-treatment tumor concentrations of PGE2	12 weeks	No
Secondary	Downstream effects of inhibition of cyclooxygenase 2 function	A difference in location of the mRNA expression of the two cohorts will be tested for using the Wilcoxon rank sum test. A difference in the immunohistochemistry staining of the two cohorts will be tested for using polytomous logistic regression	12 weeks	No
Secondary	Response Rate	Radiographic repsonse will be measured using RECIST critera in patients with unresectable esophageal cancer.	4 years	No